Please use this identifier to cite or link to this item:
|Title:||Natural killer cell engineering for cellular therapy of cancer|
Natural killer cells
|Citation:||Shook, D.R., Campana, D. (2011-12). Natural killer cell engineering for cellular therapy of cancer. Tissue Antigens 78 (6) : 409-415. ScholarBank@NUS Repository. https://doi.org/10.1111/j.1399-0039.2011.01796.x|
|Abstract:||Natural killer (NK) cells can kill transformed cells and represent a promising tool for the treatment of cancer. Their function is governed by a balance of stimulatory and inhibitory signals triggered by surface receptors. Advances in NK cell therapy require the development of dependable methods for obtaining an adequate number of effector cells; additional activation or genetic modification may further increase their anticancer capacity. A method for NK cell expansion used in our laboratory relies on a genetically modified form of the K562 myeloid leukemia cell line, engineered to express a membrane-bound form of interleukin-15 and the ligand for the costimulatory molecule 4-1BB (CD137). Expanded NK cells can be transduced with genes encoding chimeric antigen receptors that stimulate tumor cell-specific cytotoxicity. These methods for NK cell expansion and genetic modification have been adapted to large-scale, clinical-grade, Current Good Manufacturing Practice conditions and support two active clinical trials. Summarized are current efforts for NK cell immunotherapy for cancer and future perspectives. © 2011 John Wiley & Sons A/S.|
|Source Title:||Tissue Antigens|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jun 15, 2018
WEB OF SCIENCETM
checked on May 15, 2018
checked on May 31, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.